Beyond Biotech - the podcast from Labiotech
Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.
Episodes
152 episodes
Special Episode: The 2025 BIO International Convention
Much of the attention of the biotech industry has been focused on the city of Boston this week as the annual BIO International Convention hit town. BIO is the world’s largest partnering conference for the biopharma industry a...
•
Episode 152
•
38:20
Alex Telford on AI, drug discovery, digital twins, and the most interesting questions in biotech
What are the most interesting questions in biotech, and is it even possible to find answers to those questions?Alex Telford is the co-founder of Convoke and a biotech blogger from the San Francisco Bay Area. His blog post, '
•
Episode 151
•
46:26
Corporate venture capital and biotechnology in 2025: challenges, opportunities, and threats
When biotechs start fundraising they regularly turn to the venture capital market seeking investment. The pool of VC money can be large, and part of that pool is corporate venture capital. Backed by firms keen to identify the next big thing in ...
•
Episode 150
•
42:12
The state of biotech finance and fundraising in Q2 2025 with Baker McKenzie
Biotechnology has always been a dynamic domain, but the world of finance that provides the fuel for the fire is just as vibrant. Trying to predict where the market for biotech investment is heading is always risky but for experts like Baker McK...
•
Episode 149
•
39:27
How generative AI and 'Photoshop for proteins' are transforming biopharma R&D
Generative artificial intelligence (GenAI) is already changing how people research, communicate, and interact, but its biggest impacts on biotech are still to come.Cradle is a Dutch-Swiss biotech startup founded in 2021 that has d...
•
Episode 148
•
35:00
Fighting mucopolysaccharidosis type I, a rare disease, by reprogramming B-cells
There are cell therapies, gene therapies, and biologics – and then there is Immusoft. Immusoft sits at the nexus point of some of the most innovative approaches in biopharma, and their Immune System Programming platform is un...
•
Episode 147
•
33:52
Inside Flagship Pioneering's strategy: How this VC turns ideas into biotech giants
Flagship Pioneering doesn't go out to find the next big thing in biotech when investing their billions in fund capital - instead, they take a different route.Flagship Pioneering has founded more than 100 companies in the life scie...
•
Episode 146
•
44:25
TCR-NK: A novel cell therapy transforming cancer treatment
Are TCR-NK treatments the next big thing in cell therapies for cancer patients?As biotechs and pharma companies continue to innovate to address patient needs in oncology, T-cell receptor therapies, or TCR-Ts, are attracting signif...
•
Episode 145
•
34:00
AI in biotech today, and how it will impact the industry tomorrow
AI is driving innovation across industries, including biotech, but where is its influence felt most and what opportunities for future impact are emerging?David del Bourgo is the co-founder and CEO of WhiteLab Genomics, an innovati...
•
Episode 144
•
39:40
How nanobodies will revolutionize immunotherapy
From llamas and camels to humans worldwide. Nanobodies are enjoying success in the clinic and experts are hailing these camelid-derived biologics as one of the next big things in immunotherapy.Kristian Reich is co-founder and CSO ...
•
Episode 143
•
41:13
Meeting the global demand for cell therapies: scaling with smart manufacturing
Cell therapies are at the cutting edge of personalized medicine but as demand for these therapies grows, how will the industry scale manufacturing to meet patient needs?Fabian Gerlinghaus is co-founder and CEO of Cellares. He and ...
•
Episode 142
•
39:38
Treating spinal cord injuries with stem cells
Spinal cord injuries impact millions of people worldwide and, unlike many chronic injuries, they usually arrive with no forewarning, impacting the young and old alike.Brian Culley is CEO of Lineage Cell Therapeutics and his compan...
•
Episode 141
•
33:48
Are mitochondrial therapeutics about to go mainstream?
Mitochondria are famously the powerhouse of the cell, but will mitochondrial therapeutics power the next big mainstream medical breakthrough?Klaus Dugi is CEO of Vandria, a biotech that develops mitophagy inducers that rejuvenate ...
•
Episode 140
•
37:47
Fighting Alzheimer's with innovative stem cell therapies
Regeneration Biomedical has developed a new technique to address neurodegenerative diseases like Alzheimer's using stem cell therapy.Dr. Christopher Duma, has long been an innovator in neurosurgery using a gamma knife radiosurgery...
•
Episode 139
•
41:51
[Rebroadcast] How AI immune system mapping can boost drug discovery
We’re taking a short break this week and, while we’re away, we invite you to enjoy one of our favorite episodes. We will return with a brand-new episode next week!Immunai is mapping the immune system at unprecedented scale and granula...
•
Episode 138
•
28:53
The TCR-T cell therapies of tomorrow
Sweden's fastest growing private biotech, Anocca, is making plans for clinical trials in pancreatic cancer, with the TCR-T cell therapy trials called VIDAR-1.The CEO, Reagan Jarvis, when a researcher, pitched the company idea to a...
•
26:42
Can RNA drugs solve the obesity epidemic?
Resalis Therapeutics is pursuing a groundbreaking approach to obesity treatment.Unlike current therapies that primarily focus on appetite suppression, Resalis’ lead program, RES-010, is a non-coding RNA drug candidate that targets...
•
29:56
Reversing cancer mechanisms to fight back against solid tumors
CatalYm is preparing to initiate its broad phase 2b clinical development program for visugromab to tackle multiple solid tumor indications. Visugromab is a monoclonal antibody that neutralizes the tumor-derived growth differe...
•
21:24
Targeting the dark genome to develop new therapies to fight obesity
In the fall of 2024, Haya Therapeutics, based in Switzerland and San Diego, landed a $1bn deal with Eli Lilly to apply its long non-coding RNA (ncRNA) technology to obesity.The company’s lead candidate, HTX-001, is making progress...
•
32:32
Can Tumor Activated Therapy kill solid tumors?
Solid tumors present a big challenge for current treatments. However, a new approach might provide the answers - Tumor Activated Therapy. By targeting specific proteins common in all solid tumor micro-environments, Seekyo sci...
•
31:22
J.P. Morgan Annual Healthcare Conference 2025: trends and highlights you may have missed
This week, we take a look at some of the highlights from the 43rd Annual J.P. Morgan Healthcare Conference, which took place in San Francisco recently.While there weren’t necessarily many financial blockbusters, there were plenty ...
•
19:57
Venture capital co-creation: The next big thing in biotech investment?
Jessica Owens and Iana Dimkova are co-founders of Initiate Ventures—a female-led venture capital firm and studio that launched recently with a $45 million debut fund.Initiate Ventures is shaking up the traditional venture capital ...
•
37:22
Developing non-opioid pain drugs
Brixton Biosciences, a clinical-stage life sciences company spun out from Massachusetts General Brigham, has been awarded $2m from the NIH HEAL Initiative to support the development of non-opioid, injectable pain relief solutions....
•
33:01